Pharmacists and physicians at University of Michigan Health knew they had a slam-dunk collaboration on their hands.

Only 1 in 10 people with diabetes in low- and middle-income countries are getting evidence-based, low-cost comprehensive care.

A team explores the possible association between genetic variants in the human genome and liver attenuation.  

Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.

New findings give reason to pay attention to metabolic dysfunction well before middle age.

While insulin comprises a big part of diabetes expenses for children and adults, diabetes-related supplies can cost even more.